In this video, Tara C. Gangadhar, MD, answers the question posed in the title of her talk by presenting immunotherapy as the precipitant for unprecedented advances in cancer therapeutics. In so doing, Dr. Gangdahar reviews the mechanisms and indications for the checkpoint blockade agents, examines their respective risk/benefit profiles, and the efficacy, immune-related toxicities, and immune adverse events arising from immunotherapy. In addition, Dr. Gangadhar offers predictions for toxicity management in the wake of increasing drug approvals and indications.
Related Links
Published
July 20, 2017
Created by
BROADCASTMED